SCHEMBL18960504

SCHEMBL18960504

CCC(=O)c1ccc(-c2nc(-c3cccc(C)c3)c(-c3ccncc3)[nH]2)cc1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.78
CSNK1D P48730 7/20 0.78
CSNK1E P49674 7/20 0.78
RAF1 P04049 2/20 0.56
ALOX5 P09917 1/20 0.55
BRAF P15056 2/20 0.54
MAPK13 O15264 1/20 0.54
MAPK12 P53778 1/20 0.54
MAPK11 Q15759 1/20 0.54
BRDT Q58F21 1/20 0.54
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18960500 0.88 MAPK14 (0.83) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL17002188 0.88 MAPK14 (1.00) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL17002187 0.87 MAPK14 (1.00) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL17002180 0.85 MAPK14 (1.00) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL18960503 0.84 MAPK14 (0.83) MAPK14CSNK1DCSNK1ERAF1BRAF
SCHEMBL17002319 0.83 MAPK14 (1.00) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL18960539 0.81 MAPK14 (0.77) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL18960502 0.81 MAPK14 (0.84) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL18966276 0.81 MAPK14 (1.00) MAPK14CSNK1DCSNK1ERAF1ALOX5
SCHEMBL17002185 0.81 MAPK14 (0.72) MAPK14CSNK1DCSNK1ERAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166867-A1 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166867-A1 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS CSNK1A1, CSNK1G1, CSNK2A1 MAPK14 241/4885CSNK1D 11/4885CSNK1E 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.